TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email. Trusted by 2500+ biotech and pharma professionals.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | January 8 - 11, 2026
🧬 Merck & Co. reportedly in talks to acquire Revolution Medicines for $28-32B amid competing buyout rumors, Roche + MediLink partner on B7H3-targeted ADC YL201 - $570M upfront and near-term milestones, Orca Bio raises $250M Series F for cell therapy commercialization and pipeline advancement, Novartis to build fourth US radioligand therapy manufacturing facility in Florida as part of $23B investment, AirNexis Therapeutics debuts with $200M series A funding to develop China-sourced COPD therapy AN01, Eikon Therapeutics files IPO for their immuno-responsive cancer treatments including TLR7/8 dual-agonist, Eli Lilly + Chai Discovery partner on AI drug design using Chai 1 and Chai 2 platforms
Biotech & Pharma Updates | January 7 - 8, 2026
🧬 Parabilis raises $305M Series F, advancing cancer drug zolucatetide toward registration, Genmab + Anthropic partner on Claude-powered AI systems for clinical development operations, Eli Lilly's Zepbound (tirzepatide)-Taltz combo shows Ph3b success in psoriatic arthritis patients with obesity, Pfizer + Gordian Bio partner on obesity target discovery using in vivo genomics platform, Massachusetts biopharma VC funding hits $6.85B in 2025 & analysts optimistic for 2026 recovery, Aktis raises $318M IPO - developing radiopharmaceutical drugs targeting cancer tumors, Alveus Therapeutics launches with $160M Series A to advance MariTide-like obesity drug ALV-100
Biotech & Pharma Updates | January 6 - 7, 2026
🧬 Eli Lilly to acquire Ventyx Biosciences for $1.2B to expand oral immune drug pipeline, Soley Therapeutics raises $200M Series C to advance oncology assets to clinic, GSK's bepirovirsen shows potential as first finite six-month treatment for chronic hepatitis B, Rakuten Medical raises $100M funding for light-based cancer therapy toward 2028 FDA filing, Poplar Therapeutics launches with $50M Series A to advance PHB-050 as a next-generation anti-IgE therapy for food allergy, Celltrion opens first US manufacturing plant in New Jersey for $330M to stabilize supply chain, Relation Therapeutics + Deerfield team up to build newcos around AI-identified drug targets, Eli Lilly + InduPro partner on cancer treatment discovery using AI platform with a total potential deal size of $950M
Biotech & Pharma Updates | January 5 - 6, 2026
🧬 Amgen to acquire Dark Blue Therapeutics for up to $840M to expand protein-degrading cancer pipeline, Arrowhead Pharma's ARO-INHBE doubles tirzepatide weight loss in type 2 diabetes patients in Ph1/Ph2a trial, Pfizer + Cartography Biosciences partner on tumor-selective antigen discovery - $65M upfront w/ $850M total potential, GSK's Exdensur (depemokimab) wins Japan approval for severe asthma and chronic rhinosinusitis with nasal polyps, Eli Lilly + Nimbus Therapeutics partner on preclinical oral obesity drug - $55M upfront + $1.3B biobucks, Bright Minds Biosciences' BMB-101 shows positive Ph2 results for drug-resistant absence seizures and developmental epilepsies, Mediar Therapeutics raises $76M Series B for clinical trials of fibrosis drugs
Biotech & Pharma Updates | January 4 - 5, 2026
🧬 Novo Nordisk launches oral Wegovy in US at $149 monthly out-of-pocket price - shares rise 2.6%, Moderna files for approval of mRNA-1010 seasonal influenza vaccine for adults aged 50 and older, Aktis Oncology aims for $209M IPO, developing miniprotein radiopharmaceuticals for cancer, Servier + Insilico Medicine partner on AI-driven oncology drug discovery in $32M upfront & $888M total deal, Incyte's Monjuvi (tafasitamab) shows Ph3 success in first-line diffuse large B-cell lymphoma - FDA filing planned, Neumora Therapeutics reports positive Ph1b results for NMRA-511 vasopressin 1a receptor antagonist in Alzheimer's disease agitation, Daiichi Sankyo plans $1.9B global Enhertu manufacturing investments across Japan, U.S., Germany, China
Biotech & Pharma Updates | January 1 - 4, 2026
🧬 Insilico Medicine’s long-awaited IPO hits the Hong Kong Stock Exchange - raises $296M for AI-driven drug discovery platform, BioMarin Pharmaceutical to acquire Amicus Therapeutics for $4.8 billion in all-cash deal, Sanofi to acquire Dynavax Technologies for $2.2B to gain hepatitis B vaccine Heplisav-B, Roche's Lunsumio (mosunetuzumab) subcutaneous formulation wins FDA approval for relapsed or refractory follicular lymphoma, Aktis Oncology files IPO for their radiopharmaceutical miniprotein radioconjugates for cancer treatment, Shionogi acquires Mitsubishi Tanabe Pharma's ALS drug Radicava for $2.5 billion, AbbVie + Suzhou Zelgen Biopharmaceuticals partner on trispecific DLL3 asset ZG006 - $100M upfront & $1.2B total w/biobucks, Boehringer Ingelheim's Jascayd wins FDA approval for progressive pulmonary fibrosis targeting phosphodiesterase 4B
Biotech & Pharma Updates | December 17 - 18, 2025
🧬 Novo Nordisk files CagriSema (cagrilintide/semaglutide) for FDA approval targeting amylin-GLP-1 pathways in obesity, Athira Pharma + Sermonix Pharmaceuticals partner on breast cancer drug lasofoxifene for $34.9M equity + $100M milestones, Insilico Medicine aims for $292M IPO on the Hong Kong Stock Exchange, AI-powered drug discovery and development platform, Novartis builds largest global R&D hub outside Switzerland in India with 9,000 employees, Orum Therapeutics raises $100M funding, degrader-antibody conjugates for cancer treatment, Syremis Therapeutics launches with $165M Series A to develop M1/M4 muscarinic drug rivaling BMS’s Cobenfy for schizophrenia
Biotech & Pharma Updates | December 16 - 17, 2025
🧬 Addition Therapeutics emerges from stealth with $100M to develop novel gene therapies for chronic + rare diseases, Merck & Co.'s Keytruda (pembrolizumab) plus Padcev hits Ph3 endpoints in perioperative muscle-invasive bladder cancer treatment, Boehringer Ingelheim + Galux partner on AI-driven precision protein design research using GaluxDesign platform, Alnylam Pharmaceuticals invests $250M to expand RNAi manufacturing facility using new enzymatic ligation technology, Cascade Pharmaceuticals raises $46M Series B for phase III trials and pipeline development, BMS + Harbour BioMed collaborate on multi-specific antibodies - $90M upfront + $1.035B milestones, Johnson & Johnson's Rybrevant Faspro (amivantamab) receives FDA approval as first subcutaneous EGFR-targeted non-small cell lung cancer therapy
Biotech & Pharma Updates | December 15 - 16, 2025
🧬 Genentech + Caris Life Sciences collaborate on AI-driven cancer target discovery with $25M upfront + $1.1B milestones, Link Cell Therapies debuts with $60M series A for logic-gated CAR-T platform, Allink Biotherapeutics raises $47M Series A extension to advance ADC clinical programs, Ambros Therapeutics launches with $125M Series A to advance Italian non-opioid pain drug neridronate, Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for $315M, Fosun Pharma acquires 53% stake in Green Valley Pharmaceuticals for $200M - reviving Alzheimer's drug GV-971, GSK's Exdensur (depemokimab) wins FDA approval for severe eosinophilic asthma treatment following Ph3 trials, Pfizer plans 15 obesity trials next year to replace $17 billion patent cliff revenue loss
Biotech & Pharma Updates | December 14 - 15, 2025
🧬 Chai Discovery raises $130M Series B for AI-powered drug design suite development, XOMA Royalty acquires Generation Bio for $4.29 per share plus contingent value rights, Novo Nordisk launches Ozempic in India - pricing lowest dose at $24 weekly for diabetes market, Link Cell Therapies raises $60M Series A to develop next-gen CAR-T therapies, Kyverna Therapeutics' miv-cel CAR-T therapy meets Ph2 endpoints for stiff person syndrome, Adaptive Biotechnologies + Pfizer partner on TCR platform for rheumatoid arthritis in up to $890M biobucks deal, Sanofi in-licenses Adel Therapeutics Alzheimer's antibody ADEL-Y01 for $80M upfront and up to $1.04B total deal value, FDA approves AstraZeneca and Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) for first-line HER2-positive metastatic breast cancer
Biotech & Pharma Updates | December 11 - 14, 2025
🧬 William Blair predicts biotech sector will outperform 2021-24 bear markets in 2026 outlook, CIRM approves $160M funding for regenerative medicine research and clinical trials, Zealand Pharma seeks brain-targeting obesity treatment partners - explores shuttle technology collaborations, Tenaya Therapeutics raises $60M public offering to develop heart disease therapies, Sobi acquires Arthrosi Therapeutics for $950M upfront - adding gout treatment pozdeutinurad to pipeline, Anixa Biosciences' alpha-lactalbumin vaccine shows positive Ph1 results for triple-negative breast cancer prevention, Innovent Biologics' mazdutide (GLP-1/glucagon dual agonist) shows significant weight loss in Ph1b obesity trial in Chinese adolescents, FDA expands Johnson & Johnson's Akeega (abiraterone/niraparib) approval for BRCA2-mutated metastatic castration-sensitive prostate cancer
![The $4 Million Problem [Guest Post]](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=800,height=421,fit=scale-down,onerror=redirect/uploads/publication/thumbnail/5a180b8a-b34c-48db-a2ed-64c17f43d4d9/landscape_Screenshot_2025-11-27_at_10.21.52_PM.png)